Gamco Investors INC. ET AL Trims Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gamco Investors INC. ET AL cut its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 18.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,600 shares of the company's stock after selling 24,100 shares during the quarter. Gamco Investors INC. ET AL's holdings in Teva Pharmaceutical Industries were worth $2,327,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TEVA. Stifel Financial Corp lifted its holdings in Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock worth $1,196,000 after buying an additional 23,283 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $198,000. Barclays PLC increased its position in shares of Teva Pharmaceutical Industries by 31.7% in the 3rd quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Sanctuary Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after purchasing an additional 664 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 2.0 %

Shares of NYSE TEVA traded up $0.28 during mid-day trading on Wednesday, reaching $14.28. The company had a trading volume of 3,699,811 shares, compared to its average volume of 12,357,216. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a 50 day simple moving average of $15.33 and a two-hundred day simple moving average of $17.62. The stock has a market cap of $16.19 billion, a P/E ratio of -9.85, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEVA. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Monday, April 14th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.